RT Journal Article SR Electronic T1 Two Billion Infected: An Inexpensive Method to Measure Latent Toxoplasmosis and its Economic Consequences* JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.07.27.24311112 DO 10.1101/2024.07.27.24311112 A1 Achtziger, Anja A1 Alós-Ferrer, Carlos A1 Garagnani, Michele YR 2024 UL http://medrxiv.org/content/early/2024/07/29/2024.07.27.24311112.abstract AB Over two billion people worldwide are infected with the protozoan Toxoplasma gondii, which influences human behavior and cognition. Standard diagnosis methods involve costly medical tests, which prevents widespread testing and hinders the study of the infection’s effects. We propose and validate an inexpensive and easy-to-deploy diagnostic method for latent Toxoplasmosis infections using response times and finite-mixture models. A clinical study showed that the method is sensitive and accurate. A large, representative UK study showed that the infection’s consequences are relevant and pervasive, both economically (decrease in yearly income and employment) and behaviorally (increase in risky behaviors, stress, and depression).Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunded by the research budget of Carlos Alos-Ferrer while affiliated with the Center for Neuroeconomics at the University of Zurich (Switzerland)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Subjects Committee of the Faculty of Economics of the University of Zurich (OEC-IRB-2022-077) and the Ethics Committee in the Canton of Zurich (BASEC:2023-00366).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRaw data files for each study and the code for the analyses are available on OSF. https://osf.io/j2rku/?view_only=482ca01c948044a08f5a8244172d4090